

Asco 2020 starts to take shape



Amy Brown

The biggest cancer conference of the year – this time coming via your computer screen – is four weeks away, and its contents are starting to emerge. Asco released thousands of abstract titles overnight, and *Evaluate Vantage* has scoured for some of the highest-profile releases. The highlight of the plenary session is likely to be the Adaura study of Astrazeneca’s lung cancer drug Tagrisso; the [maintenance setting trial was stopped much earlier than expected](#) for “overwhelming efficacy”. The Javelin Bladder 100 data on Pfizer and Merck KGaA’s also-ran PD-(L)1 checkpoint inhibitor will also be a draw: Bavencio [scored a surprise hit](#) in bladder cancer, albeit a maintenance setting, earlier this year. Also of interest will be results from the investigator-sponsored front-line multiple myeloma trial of Amgen’s Kyprolis, Endurance. The drug failed in another newly diagnosed patient study, Clarion, a few years back, albeit as part of a different combination; the fact that no topline results have been reported is probably not encouraging. Outside the plenary, data on Roche’s anti-Tigit project will attract much attention, as will sessions examining the impact of Covid-19 on patients with cancer.

Selected notable Asco presentations

Company	Project	Presentation	Abstract
Astrazeneca	Tagrisso	Adaura lung cancer maintenance study*	LBA5
Pfizer, Merck KGaA	Bavencio	Javelin Bladder 100 phase III interim analysis*	LBA1
Merck & Co	Keytruda	Keynote-177 study in MSI-high/MMR-deficient colorectal cancer*	LBA4
Amgen	Kyprolis	Endurance study in newly diagnosed multiple myeloma*	LBA3
Roche	Tiragolumab	Primary analysis of phase II Cityscape study, in 1L PD-L1-selected NSCLC	9503
Lilly	Selpercatinib	Ret-fusion +ve NSCLC	3584
Bristol-Myers Squibb	Opdivo + Yervoy + chemo	Checkmate-9LA; 1L NSCLC (known to have succeeded)	9501
Astrazeneca/Daiichi Sankyo	Enhertu	Destiny-CRC01, in Her2 +ve metastatic colorectal cancer	4000
Astrazeneca/Daiichi Sankyo	Enhertu	Destiny-Gastric01, in Her2 +ve advanced gastric cancer (known to have succeeded)	4513
Astrazeneca/Daiichi Sankyo	Enhertu	Interim results from Destiny-Lung01, in patients with Her2-mutated NSCLC	9504
Merck & Co	Keytruda	Keynote-355, in metastatic triple-negative breast cancer (known to have succeeded)	1000
Merck & Co	Keytruda	Keynote-604, in 1L extensive-stage SCLC (known to have failed)	9001
Clinical science symposium		Data from the Covid-19 and Cancer Consortium (CCC19)	LBA110
Clinical science symposium		Impact of type of cancer therapy and Covid-19 therapy on survival	LBA111

*Plenary session on Sunday May 31. Source: Asco & company statements.

